Strides To Arm GLP-1 Generics Ahead Of LoEs, As Novo Spars Over Semaglutide Capacity
Primed To Tap $60bn Opportunity
Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting.
